adalimumab vs JNJ-78934804

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody (fully human IgG1)
Partial signal

NCT00055497 · Phase 3 · completed

Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.

Next expected readout: June 2027 · NCT06045754 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)

Result source: NCT02499783

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Crohn's DiseaseCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07577843 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabJNJ-78934804
Clinical remission (induction)37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
—Trial running · NCT07577843
Endoscopic response (induction)—Trial running · NCT05040464—Trial running · NCT07577843
Clinical remission (maintenance)47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
—Trial running · NCT07577843
Endoscopic response (maintenance)—Trial running · NCT05040464—Trial running · NCT07577843

Clinical remission (induction)

adalimumab
37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
JNJ-78934804
—Trial running · NCT07577843

Endoscopic response (induction)

adalimumab
—Trial running · NCT05040464
JNJ-78934804
—Trial running · NCT07577843

Clinical remission (maintenance)

adalimumab
47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
JNJ-78934804
—Trial running · NCT07577843

Endoscopic response (maintenance)

adalimumab
—Trial running · NCT05040464
JNJ-78934804
—Trial running · NCT07577843
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Dropout rate
—40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
15.8%40 mg every other week
NCT00055497 · Phase 3
11.1%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
40.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
48.5%
NCT00195715 · Phase 3
16.9%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.4%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
6.8%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
6.8%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
21.4%
NCT02185014 · Phase 3 · monotherapy
61%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
34.4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
35.7%80 mg
NCT01958827 · Phase 3 · monotherapy
16.4%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
36%
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
26.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
5.3%40 mg every other week
NCT00055497 · Phase 3
5.6%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
12.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
15.7%
NCT00195715 · Phase 3
6%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1.5%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
3.9%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
2.4%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
7.1%
NCT02185014 · Phase 3 · monotherapy
8%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
21.9%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
10.7%80 mg
NCT01958827 · Phase 3 · monotherapy
10.9%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
—
NCT02148718 · Phase 4 · registry result, not featured evidence
20%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
20%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
Serious AEs
5.3%40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
—40 mg every other week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
0%40 mg every week
NCT00055497 · Phase 3
16.7%40 mg
NCT00055497 · Phase 3
2%160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
38.1%
NCT00195715 · Phase 3
—40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
14.8%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.5%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.9%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.6%Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
6.4%Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
10.7%
NCT02185014 · Phase 3 · monotherapy
48%
NCT00686374 · Phase 3 · monotherapy
23.7%40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20%20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
8%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
40.6%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
28.6%80 mg
NCT01958827 · Phase 3 · monotherapy
—40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
2.3%
NCT02148718 · Phase 4 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
7.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
14.3%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weeka
nasopharyngitis 26.3% (placebo 38.9%)
crohn's disease aggravated 21.1% (placebo 27.8%)
sinusitis 21.1% (placebo 5.6%)
NCT00055497 · Phase 3
show 28 more results
40 mg every week
crohn's disease aggravated 11.1% (placebo 27.8%)
dizziness (excl vertigo) 11.1% (placebo 5.6%)
nasopharyngitis 11.1% (placebo 38.9%)
NCT00055497 · Phase 3
40 mg
crohn's disease aggravated 17.6% (placebo 27.8%)
nasopharyngitis 16.7% (placebo 38.9%)
headache 14% (placebo 11.1%)
NCT00055497 · Phase 3
160/80 mg
white blood cell count decreased 5.9% (placebo 1%)
cough 4.9% (placebo 0%)
dizziness 3.9% (placebo 0%)
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 39.8%
nasopharyngitis 26.1%
arthralgia 24.7%
NCT00195715 · Phase 3
40 mg every other week or every week
headache 18.9%
nasopharyngitis 14.4%
arthralgia 7.6%
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 23.4% (placebo 29.2%)
headache 14.1% (placebo 9.2%)
nasopharyngitis 14.1% (placebo 12.3%)
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nasopharyngitis 6.2%
headache 5.5%
crohn's disease 4.5%
NCT02065570 · Phase 3 · monotherapy
headache 8.7%
arthralgia 7.8%
nausea 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 14.7%
nasopharyngitis 13.8%
headache 8.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 13.8%
nasopharyngitis 9.2%
headache 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 11.9%
arthralgia 7.1%
nausea 6%
NCT02185014 · Phase 3 · monotherapy
viral upper respiratory tract infection 39%
headache 37%
upper respiratory tract infection 31%
NCT00686374 · Phase 3 · monotherapy
40 mg or 20 mg every other week
headache 17.2%
crohn's disease 11.8%
nausea 10.8%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20 mg or 10 mg every other week
headache 21.1%
crohn's disease 15.8%
nasopharyngitis 11.6%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
40 mg Eow
nasopharyngitis 56% (placebo 12%)
rhinorrhoea 16% (placebo 0%)
adverse drug reaction 12% (placebo 4%)
NCT00445432 · Phase 2/3 · monotherapy
40 mg Eow
nasopharyngitis 71.9% (placebo 12%)
adverse drug reaction 18.8% (placebo 4%)
iron deficiency anaemia 18.8% (placebo 0%)
NCT00445432 · Phase 2/3 · monotherapy
160 mg/80 mg + 40/40 mg
adverse drug reaction 11.1% (placebo 4.3%)
application site swelling 11.1% (placebo 0%)
blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
160 mg/80 mg
headache 9.1% (placebo 4.3%)
upper respiratory tract infection 9.1% (placebo 4.3%)
abdominal distension 6.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80/40 mg + 40/40 mg
headache 16.7% (placebo 4.3%)
abdominal distension 8.3% (placebo 0%)
abdominal pain 8.3% (placebo 4.3%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg/40 mg
injection site reaction 8.8% (placebo 8.7%)
malaise 8.8% (placebo 0%)
rhinorrhoea 8.8% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg
nasopharyngitis 46.4%
rash 14.3%
headache 10.7%
NCT01958827 · Phase 3 · monotherapy
40 mg every other week
crohn's disease 16.1%
abdominal pain 7.6%
injection site reaction 7.6%
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
arthralgia 18.2%
crohn's disease 16.4%
nasopharyngitis 10.9%
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
vomiting 7%
abdominal mass 5.8%
arthralgia 4.7%
NCT02148718 · Phase 4 · registry result, not featured evidence
Low Induction Dose
leukopenia 20%
pyrexia 13.3%
arthralgia 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Low Induction Dose
leukopenia 15.4%
animal bite 7.7%
aphthous stomatitis 7.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
alanine aminotransferase increased 13.3%
aspartate aminotransferase increased 13.3%
abdominal pain 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
mycobacterium tuberculosis complex test positive 14.3%
aspartate aminotransferase increased 7.1%
asthenia 7.1%
NCT02015793 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Clinical Remission 57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
show 11 more results
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
36.3% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 74 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
66.7% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 12 Participants as posted
78.9% (n=19) vs 44.4% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
83.3% (n=18) vs 44.4% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
40.2% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 82 Participants as posted
38.1% (n=21) vs 9.1% (n=22) placebo @ 52wk*40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy · converted to % from 8 Participants as posted
32.8% (n=64) vs 9.2% (n=65) placebo @ 52wk*
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 21 Subjects as posted
Clinical Remission 14.3% (n=28) @ 4wk80 mg
responder rate · % of participants
No placebo or comparator arm
NCT01958827 · Phase 3 · monotherapy
show 80 more results
25% (n=28) @ 8wk80 mg
NCT01958827 · Phase 3 · monotherapy
28.6% (n=28) @ 12wk80 mg
NCT01958827 · Phase 3 · monotherapy
32.1% (n=28) @ 16wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 20wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 24wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 28wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 32wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 36wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 40wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 44wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 48wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 52wk80 mg
NCT01958827 · Phase 3 · monotherapy
36.3% (n=204) @ 56wk*40 mg
NCT00055497 · Phase 3 · converted to % from 74 Participants as posted
45.6% (n=204) @ 56wk*40 mg
NCT00055497 · Phase 3 · converted to % from 93 Participants as posted
38.7% (n=93) @ 26wk40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
33.3% (n=93) @ 52wk40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
28.4% (n=95) @ 26wk20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
23.2% (n=95) @ 52wk20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60% (n=55) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
54.5% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
59.4% (n=609) @ 48wk
NCT00195715 · Phase 3
68.8% (n=462) @ 108wk
NCT00195715 · Phase 3
69.5% (n=272) @ 156wk
NCT00195715 · Phase 3
46.7% (n=15) @ 204wk
NCT00195715 · Phase 3
43.7% (n=206) @ 4wk
NCT02065570 · Phase 3 · monotherapy
43.5% (n=308) @ 4wk
NCT02065570 · Phase 3 · monotherapy
51.5% (n=206) @ 12wk
NCT02065570 · Phase 3 · monotherapy
62.3% (n=308) @ 12wk
NCT02065570 · Phase 3 · monotherapy
89.2% (n=65) @ 0wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
84.6% (n=65) @ 4wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 55 Participants as posted
89.2% (n=65) @ 8wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
81.5% (n=65) @ 12wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 53 Participants as posted
83.1% (n=65) @ 24wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 54 Participants as posted
80% (n=65) @ 36wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
73.8% (n=65) @ 48wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 48 Participants as posted
75.4% (n=65) @ 60wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 49 Participants as posted
72.3% (n=65) @ 72wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 47 Participants as posted
70.8% (n=65) @ 84wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 46 Participants as posted
69.2% (n=65) @ 96wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 45 Participants as posted
69.2% (n=65) @ 108wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 45 Participants as posted
64.6% (n=65) @ 120wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 42 Participants as posted
61.5% (n=65) @ 144wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 40 Participants as posted
53.8% (n=65) @ 168wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 35 Participants as posted
47.7% (n=65) @ 192wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 31 Participants as posted
41.5% (n=65) @ 216wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 27 Participants as posted
40% (n=65) @ 240wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 26 Participants as posted
35.4% (n=65) @ 264wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
26.2% (n=65) @ 288wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 17 Participants as posted
23.1% (n=65) @ 312wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 15 Participants as posted
12.3% (n=65) @ 336wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 8 Participants as posted
10.8% (n=65) @ 360wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
1.5% (n=65) @ 384wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
54.65% (n=86) @ 2wk
NCT02148718 · Phase 4 · registry result, not featured evidence
62.79% (n=86) @ 4wk
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7% (n=15) @ 2wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
46.7% (n=15) @ 2wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
40% (n=15) @ 4wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 4wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 6wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 6wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 8wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 8wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 10wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 10wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 12wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 12wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 14wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 14wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 16wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 16wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 18wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 18wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 20wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 20wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 22wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 22wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 24wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 24wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 26wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 26wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
CR-100 57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
show 11 more results
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
CR-70 68.4% (n=19) vs 44.4% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
show 11 more results
94.4% (n=18) vs 44.4% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
60.3% (n=204) vs 44.4% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 123 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
53.9% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
94.7% (n=19) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 18 Participants as posted
94.4% (n=18) vs 83.3% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
70.6% (n=204) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 144 Participants as posted
78.9% (n=19) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
88.9% (n=18) vs 72.2% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 16 Participants as posted
72.1% (n=204) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 147 Participants as posted
IBDQ 43.4 vs 29.9 placebo score @ 24wk40 mg every other week
absolute change · score
Maintenance
NCT00055497 · Phase 3
show 6 more results
51.9 vs 29.9 placebo score @ 24wk40 mg every week
NCT00055497 · Phase 3
33.9 vs 29.9 placebo score @ 24wk40 mg every other week
NCT00055497 · Phase 3
45.7 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
45.2 vs 24.7 placebo score @ 56wk40 mg every week
NCT00055497 · Phase 3
36 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
27.8 vs 1.8 placebo score @ 52wk40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
Clinical Remission 37.3% (n=102) vs 6.8% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
46.9% (n=64) vs 27.7% (n=65) placebo @ 12wk*
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 30 Subjects as posted
CDAI 67.6% (n=102) vs 27.2% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
IBDQ Remission 40.2% (n=102) vs 20.4% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response 100 85.7% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Clinical Response 70 91.2% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Corticosteroid-free Clinical Remission 50% (n=16) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
responder rate · % of participants
No placebo or comparator arm
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
56.3% (n=16) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
63.1% (n=103) @ 156wk
NCT00195715 · Phase 3
48% (n=100) @ 12wk
NCT02065570 · Phase 3 · monotherapy
52.9% (n=155) @ 12wk
NCT02065570 · Phase 3 · monotherapy
Steroid-free Clinical Response 100 74.8% (n=103) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3

+ 62 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Partial signal

NCT00385736 · Phase 3 · completed

Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.

Next expected readout: September 2027 · NCT06257875 (registry estimate)

Reported efficacy

Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)

Result source: NCT00408629

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Ulcerative ColitisCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07577856 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabJNJ-78934804
Clinical remission (induction)10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
—Trial running · NCT07577856
Clinical remission (maintenance)20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
—Trial running · NCT07577856
Clinical response (induction)50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Trial running · NCT07577856
Endoscopic improvement (induction)44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Trial running · NCT07577856
Corticosteroid-free remission (maintenance)13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
—Trial running · NCT07577856

Clinical remission (induction)

adalimumab
10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
JNJ-78934804
—Trial running · NCT07577856

Clinical remission (maintenance)

adalimumab
20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
JNJ-78934804
—Trial running · NCT07577856

Clinical response (induction)

adalimumab
50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
JNJ-78934804
—Trial running · NCT07577856

Endoscopic improvement (induction)

adalimumab
44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
JNJ-78934804
—Trial running · NCT07577856

Corticosteroid-free remission (maintenance)

adalimumab
13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
JNJ-78934804
—Trial running · NCT07577856
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Dropout rate
6.9%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
9.2%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
37.6%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
52.5%
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
10.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.4%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
34.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Discontinued due to AEs
3.1%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
4.6%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
14.3%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5.6%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Serious AEs
4%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
3.8%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
12.1%Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.1%
NCT02632175 · Phase 3 · monotherapy
7.8%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
5.6%open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.6%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
13.9%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.2%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.8%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
5%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.6%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.8%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
9.9%Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.7%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
11.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.1%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.5%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Most frequent reported AEs
160/80/40a
colitis ulcerative 4% (placebo 3.6%)
fatigue 4% (placebo 2.2%)
headache 3.1% (placebo 7.2%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 17 more results
80/40
headache 6.9% (placebo 7.2%)
colitis ulcerative 5.4% (placebo 3.6%)
nasopharyngitis 4.6% (placebo 1.8%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 17.5% (placebo 10.4%)
colitis ulcerative 16.3% (placebo 22.3%)
headache 8.6% (placebo 14.2%)
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 33.9%
upper respiratory tract infection 27.1%
nasopharyngitis 22%
NCT02632175 · Phase 3 · monotherapy
high dose
headache 9.8% (placebo 16.7%)
anaemia 5.9% (placebo 8.3%)
nausea 5.9% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
open-label high dose
headache 22.2% (placebo 16.7%)
abdominal pain 11.1% (placebo 8.3%)
oropharyngeal pain 11.1% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 12.5% (placebo 16.7%)
colitis ulcerative 6.3% (placebo 16.7%)
nasopharyngitis 6.3% (placebo 8.3%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
high dose
colitis ulcerative 11.1% (placebo 16.7%)
nasopharyngitis 11.1% (placebo 8.3%)
upper respiratory tract infection 11.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 18.2% (placebo 16.7%)
c-reactive protein increased 9.1% (placebo 0%)
colitis ulcerative 9.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 8.4%
nasopharyngitis 5.1%
arthralgia 3.1%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 6.1%
colitis ulcerative 5.3%
nasopharyngitis 4.2%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 13.4%
nasopharyngitis 13.1%
arthralgia 6.6%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 17.4%
nasopharyngitis 13.6%
arthralgia 6.7%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 15.2%
nasopharyngitis 7.3%
upper respiratory tract infection 6%
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
40 mg EOW/EW
colitis ulcerative 30.4%
viral upper respiratory tract infection 19.4%
arthralgia 10.5%
NCT00573794 · Phase 3 · monotherapy
160 mg/80 mg
nasopharyngitis 33.3% (placebo 21.9%)
iron deficiency anaemia 8.9% (placebo 7.3%)
headache 7.8% (placebo 6.3%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
80 mg/40 mg
nasopharyngitis 21.8% (placebo 21.9%)
injection site reaction 8% (placebo 2.1%)
dental caries 6.9% (placebo 5.2%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 13.2%
headache 13%
nasopharyngitis 8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Clinical Remission 10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 6 more results
10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10% (n=130) vs 9.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.5% (n=130) vs 9.2% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.5% (n=248) vs 9.3% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 50% (n=90) vs 35.4% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
42.5% (n=87) vs 35.4% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
54.6% (n=130) vs 44.6% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
51.5% (n=130) vs 44.6% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50.4% (n=248) vs 34.6% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Rectal Bleeding Subscore 0 1 77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Physician Global Assessment Subscore 0 1 60% (n=130) vs 46.9% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
53.8% (n=130) vs 46.9% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Stool Frequency Subscore 0 1 48.5% (n=130) vs 37.7% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
36.2% (n=130) vs 37.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
IBDQ 42.2% (n=90) vs 39.6% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
48.3% (n=87) vs 39.6% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
60.8% (n=130) vs 57.7% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.8% (n=130) vs 57.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.1% (n=248) vs 45.5% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Remission 20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 14 more results
17.8% (n=90) vs 8.3% (n=96) placebo @ 32wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.2% (n=87) vs 8.3% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.3% (n=248) vs 8.5% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
29% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.2% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.3% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.5% (n=22) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
44% (n=25) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical Remission 8.5% (n=248) vs 4.1% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 37.8% (n=90) vs 20.8% (n=96) placebo @ 32wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 8 more results
31.1% (n=90) vs 17.7% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=87) vs 20.8% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
29.9% (n=87) vs 17.7% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
30.2% (n=248) vs 18.3% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
61.3% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
67.7% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
57.6% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
65.7% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical 23.8% (n=248) vs 12.2% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 44.4% (n=90) vs 30.2% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
39.1% (n=87) vs 30.2% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
41.1% (n=248) vs 31.7% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

+ 51 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · JNJ-78934804's landscape